It's Motley Fool Money's midyear review show! We talk through the market's strong start in 2024, how it's being driven by the big names, and where the deals might be.
These stocks have been crushed by the market, but could be diamonds in the rough for patient investors.
Not all cheap stocks are good buys, but these two might be.
The major banks are cashing in on high interest rates, but cracks continue to show in the picture of the consumer.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset" or the "Company") (NASDAQ: OM). Such investors...
/PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, continues its investigation on behalf of Outset Medical,...
/PRNewswire/ -- Law Offices of Howard G. Smith continues its investigation on behalf of Outset Medical, Inc. ("Outset Medical" or the "Company") (NASDAQ: OM)...
/PRNewswire/ -- The Law Offices of Frank R. Cruz continues its investigation of Outset Medical, Inc. ("Outset Medical" or the "Company") (NASDAQ: OM) on behalf...
Novo Nordisk indicated one of its diabetes drugs could also be used to treat kidney disease. Here's what investors need to know.
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of...